# An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)

Study · id `cardio:ct-nct01202058` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01202058](<https://clinicaltrials.gov/study/NCT01202058>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01202058

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 156 participants.

## Technical summary

Registry record NCT01202058. Randomized; single masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 156 participants (enrolled count; ClinicalTrials.gov record NCT01202058, source copy `cardio:ctgov-nct01202058-2012-10-25`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01202058, source copy `cardio:ctgov-nct01202058-2012-10-25`, retrieved 2026-10-26)
- Primary completion: 2011-11 (actual) (ClinicalTrials.gov record NCT01202058, source copy `cardio:ctgov-nct01202058-2012-10-25`, retrieved 2026-10-26)
- Completion: 2012-10 (actual) (ClinicalTrials.gov record NCT01202058, source copy `cardio:ctgov-nct01202058-2012-10-25`, retrieved 2026-10-26)
- Countries: Netherlands; Spain; Switzerland (ClinicalTrials.gov record NCT01202058, source copy `cardio:ctgov-nct01202058-2012-10-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01202058-2012-10-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)
- Acronym: NEVO II
- Condition: Atherosclerotic Coronary Artery Disease
- Intervention (Device): NEVO™ Sirolimus-eluting Coronary Stent System
- Intervention (Device): XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)
- Lead sponsor: Cordis US Corp.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Cordis US Corp. (`cardio:org-cordis-us-corp`)

## Provenance

Content hash: dd4cef9d1b73ce04c9921e393e4304f5101b075b417b89a64498b63da5d05629
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
